Rhythm Pharmaceuticals shares are up about 3.33% in today’s session, extending a recent upswing tied to improving visibility for IMCIVREE (setmelanotide) beyond its legacy rare genetic obesity indications. The move appears driven by continued follow-through buying after a sequence of regulatory wins that investors view as de-risking commercial expansion in acquired hypothalamic obesity (HO).

The most recent concrete regulatory update was a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) supporting IMCIVREE for obesity and control of hunger in patients with acquired hypothalamic obesity due to hypothalamic injury or impairment (announced March 26, 2026). That opinion followed closely on the heels of a U.S. approval, reinforcing the narrative that IMCIVREE’s label is broadening into a larger, under-treated population and providing a fresh runway for growth expectations. (ir.rhythmtx.com)

For commercial-stage biopharma names, incremental label expansions can reset revenue trajectories and compress perceived risk, which often translates into higher multiples—especially after regulatory uncertainty clears. With the U.S. hypothalamic obesity approval now in place and Europe moving in the same direction, trading action suggests investors are re-underwriting peak sales potential and the durability of IMCIVREE as a franchise rather than treating HO as a one-off catalyst. (fiercepharma.com)

Next milestones center on Europe’s formal regulatory decision process following the CHMP opinion and early evidence of launch execution in the newly approved U.S. HO population, including access, reimbursement, and patient identification trends. Investors will also be sensitive to any capital markets activity or other balance-sheet moves, given prior offerings can create near-term trading overhangs even when fundamentals are improving. (api.finexus.net)